On October 1, 2026 Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum platform, reported its participation in the 17th World ADC San Diego, taking place October 12–15, 2026, in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.
Defence to Lead Discussion on the Next Frontier in ADC Development:
As part of the conference program, Dr. Amie Phinney, President and Chief Executive Officer of Defence Therapeutics, will take the stage on Wednesday, October 14, at 12:30 p.m. for a presentation and fireside discussion entitled "Beyond Antibody, Linker & Payload – Is Intracellular Delivery the Next Frontier for ADCs?"
The discussion will explore how intracellular trafficking and processing can influence ADC activity; whether improving intracellular delivery could enhance the performance of existing ADCs or create opportunities for ADCs in development; and how emerging technologies may help address these challenges.
The session provides an opportunity for Defence to introduce the scientific rationale underlying its proprietary Accum intracellular delivery platform within the broader evolution of ADC technology and to engage with industry leaders on potential applications and collaborations.
"The ADC field has made remarkable advances in antibody engineering, linker chemistry and payload development, but intracellular delivery represents another important dimension of ADC performance," said Dr. Amie Phinney, President and Chief Executive Officer of Defence Therapeutics. "World ADC provides an ideal forum to bring together different perspectives on where the field goes next. We look forward to contributing to that discussion while exploring how Accum may complement existing and emerging ADC technologies."
In addition to its on-stage participation, Defence will present its latest Accum-ADC research during the conference scientific poster session on Tuesday afternoon. The poster, entitled "Accum: A Plug-In Intracellular Trafficking Platform for Next-Generation ADCs," will be presented by Dr. Guillaume Lefrançois, Senior Scientist at Defence Therapeutics, and will highlight the Company’s ongoing work evaluating Accum as an intracellular trafficking platform for ADCs.
Defence’s team will be available throughout the conference to meet with researchers, pharmaceutical and biotechnology companies interested in learning more about the Accum platform and Defence’s ADC-enhancement profiling programs. Those interested in connecting with Defence during World ADC San Diego are encouraged to contact the Company at [email protected]
(Press release, Defence Therapeutics, OCT 1, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-to-take-the-stage-at-world-adc-san-diego-to-discuss-the-next-frontier-in-antibody-drug-conjugates [SID1234671212])